Skip to main content

ARCH Venture Partners — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

239
Companies
$31.3B
Total invested
$131.1M
Avg. check
24
Industries
Biotechnology 20Medical 11Health Care 10Therapeutics 7Pharmaceutical 6Life Science 6+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 49–72 of 239
Pretzel Therapeutics
July 2025

Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

Biotechnology · WalthamVenture - Series Unknown
Cero Therapeutics
April 2025

CERo Therapeutics, Inc. is a new cellular immunotherapy company.

Biotechnology · South San Francisco$8.0M Post-IPO Equity
AIRNA
April 2025

AIRNA develops RNA editing technologies to create medicines for various diseases.

Biotechnology · Cambridge$155.0M Series B
Arbor Biotechnologies
March 2025

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

Artificial Intelligence (AI) · Cambridge$73.9M Series C
Genetix Biotherapeutics Inc.
February 2025

Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.

Biotechnology · SomervillePrivate Equity
Homeward
February 2025

Homeward is focused on improving access to high-quality, affordable primary and specialty care in rural communities.

Artificial Intelligence (AI) · San Francisco$12.0M Grant
Be Biopharma
January 2025

Be Biopharma develops engineered B cell medicines for serious genetic diseases.

Biopharma · Cambridge$92.0M Series C
Rhygaze
January 2025

Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.

Biotechnology · Basel$86.0M Series A
Tenvie Therapeutics
January 2025

Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.

Biotechnology · South San Francisco$200.0M Series A
Generate Biomedicines
December 2024

Generate Biomedicines is a biotech company that combines biology, machine learning, and biological engineering to create biomedicines.

Artificial Intelligence (AI) · SomervilleSeries C
Akamis Bio
December 2024

Akamis Bio is a clinical-stage oncology company.

Biotechnology · Abingdon$60.0M Series A
bit.bio
December 2024

Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.

Biotechnology · Cambridge$30.0M Venture - Series Unknown
nChroma Bio
December 2024

nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.

Biotechnology · Boston$75.0M Venture - Series Unknown
Metsera
November 2024

Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.

Biopharma · New York$215.0M Series B
Rippl Care
October 2024

Rippl Care is a mental health company committed to assisting seniors who suffer from dementia and other neurocognitive disorders.

Elder Care · Seattle$23.0M Series A
EGenesis
September 2024

EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.

Biopharma · Cambridge$191.0M Series D
ArsenalBio
September 2024

ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors.

Biotechnology · South San Francisco$325.0M Series C
Ultivue
July 2024

Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.

Biopharma · Cambridge$3.3M Venture - Series Unknown
Autobahn Therapeutics
July 2024

Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders

Biotechnology · San Diego$100.0M Series C
Advanced Medicine Partners
June 2024

Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells.

Biotechnology · Lake Forest$32.0M Series A
Vilya
June 2024

Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease.

Biotechnology · Seattle$21.0M Series A
Quantum Circuits
May 2024

Quantum Circuits is delivering a full-stack quantum computer based on the innovative dual-rail qubit providing superior performance.

Computer · New Haven$60.0M Series B
Slingshot Biosciences
April 2024

Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.

Biotechnology · Emeryville$15.0M Series A
Neumora Therapeutics
April 2024

Neumora Therapeutics operates as a clinical-stage biotechnology company.

Biotechnology · Watertown$2.6M Grant

Where ARCH Venture Partners invests

Biotechnology20
Medical11
Health Care10
Therapeutics7
Pharmaceutical6
Life Science6

About ARCH Venture Partners's portfolio

How many companies has ARCH Venture Partners invested in?▸

ARCH Venture Partners has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does ARCH Venture Partners invest in?▸

ARCH Venture Partners's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Pharmaceutical. The firm invests across 24 different industry categories.

What is ARCH Venture Partners's largest investment?▸

Among tracked funding rounds, ArsenalBio received $325.0M in a Series C round. ARCH Venture Partners's total known invested capital is $31.3B.

What is the average investment size for ARCH Venture Partners?▸

ARCH Venture Partners's average investment size is $131.1M across its portfolio of 239 companies.

What are ARCH Venture Partners's most recent investments?▸

Recent ARCH Venture Partners portfolio additions include Pretzel Therapeutics, Cero Therapeutics, AIRNA, Arbor Biotechnologies, Genetix Biotherapeutics Inc.. These companies were founded in 2020 or later.

Reach the founders behind these 239 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →